Article
Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.
Current drug targets - 1 Jul 2010
De Luca A, Normanno N
Abstract excerpt
The epidermal growth factor receptor (EGFR) and its ligands are frequently expressed in non-small-cell lung cancer (NSCLC). The EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib have shown clinical activity in NSCLC. However, only a small subgroup of NSCLC patients respond to these a...
Topics
- Biomarkers, Pharmacological
- Carcinoma, Non-Small-Cell Lung
- Drug Resistance, Neoplasm
- ErbB Receptors
- Gene Dosage
- Gene Expression Regulation, Neoplastic
- Humans
- Lung Neoplasms
- Models, Biological
- Mutation
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins
- Receptor Protein-Tyrosine Kinases